Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

BACKGROUND/PURPOSE: In Japan, there is a growing population of patients with chronic hepatitis C virus (HCV) infection who failed a direct-acting antiviral (DAA)-based regimen. In this Phase 3 study, we evaluated sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 HCV inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Namiki, Takehara, Tetsuo, Chayama, Kazuaki, Yatsuhashi, Hiroshi, Takaguchi, Koichi, Ide, Tatsuya, Kurosaki, Masayuki, Ueno, Yoshiyuki, Toyoda, Hidenori, Kakizaki, Satoru, Tanaka, Yasuhito, Kawakami, Yoshiiku, Enomoto, Hirayuki, Ikeda, Fusao, Jiang, Deyuan, De-Oertel, Shampa, McNabb, Brian L., Camus, Gregory, Stamm, Luisa M., Brainard, Diana M., McHutchison, John G., Mochida, Satoshi, Mizokami, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096959/
https://www.ncbi.nlm.nih.gov/pubmed/30030720
http://dx.doi.org/10.1007/s12072-018-9878-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096959/
https://www.ncbi.nlm.nih.gov/pubmed/30030720
http://dx.doi.org/10.1007/s12072-018-9878-6

Ejemplares similares